Barroso MTC, Hoppe MW, Boehme P, Krahn T, Kiefer C, Kramer F, Mondritzki T, Pirez P, Dinh W. Test-Retest Reliability of Non-Invasive Cardiac Output Measurement during Exercise in Healthy Volunteers in Daily Clinical Routine.
Arq Bras Cardiol 2019;
113:231-239. [PMID:
31291418 PMCID:
PMC6777898 DOI:
10.5935/abc.20190116]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2018] [Accepted: 11/14/2018] [Indexed: 12/28/2022] Open
Abstract
Background
Thoracic bioreactance (TB), a noninvasive method for the measurement of
cardiac output (CO), shows good test-retest reliability in healthy adults
examined under research and resting conditions.
Objective
In this study, we evaluate the test-retest reliability of CO and cardiac
power (CPO) output assessment during exercise assessed by TB in healthy
adults under routine clinical conditions.
Methods
25 test persons performed a symptom-limited graded cycling test in an
outpatient office on two different days separated by one week.
Cardiorespiratory (power output, VO2peak) and hemodynamic
parameters (heart rate, stroke volume, CO, mean arterial pressure, CPO) were
measured at rest and continuously under exercise using a spiroergometric
system and bioreactance cardiograph (NICOM, Cheetah Medical).
Results
After 8 participants were excluded due to measurement errors (outliers),
there was no systematic bias in all parameters under all conditions (effect
size: 0.2-0.6). We found that all noninvasively measured CO showed
acceptable test-retest-reliability (intraclass correlation coefficient:
0.59-0.98; typical error: 0.3-1.8). Moreover, peak CPO showed better
reliability (intraclass correlation coefficient: 0.80-0.85; effect size:
0.9-1.1) then the TB CO, thanks only to the superior reliability of MAP
(intraclass correlation coefficient: 0.59-0.98; effect size: 0.3-1.8).
Conclusion
Our findings preclude the clinical use of TB in healthy subject population
when outliers are not identified.
Collapse